William R. Jellison
William R. Jellison's purchase track record
William R. Jellison has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/22/2025 | MDT | $463K | +10.0% | +6.0% | +6.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MiniMed completes separation from Medtronic. Medtronic has finalized the separation of its MiniMed insulin pump business, which is now operating as an independent company with a new board of directors. This corporate restructuring marks a significant shift in Medtronic's portfolio structure. Meanwhile, the company was named to the TIME Best Inventions of 2026 list for its Stealth AXiS surgical system and Corsano wearable, highlighting continued innovation in its remaining product lines.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
Transaction History
| AVNT | ▲ Buy | Grant | 958 | $0 | 9/30/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,049 | $0 | 6/30/2026 | View on chart |
| MDT | ▲ Buy | Grant | 1,444 | $0 | 4/27/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,072 | $0 | 3/31/2026 | View on chart |
| AVNT | ▲ Buy | Grant | 1,239 | $0 | 12/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,192 | $0 | 9/30/2025 | View on chart |
| MDT | ▲ Buy | Open Market | 2,500 | $231K | 8/25/2025 | View on chart |
| MDT | ▲ Buy | Open Market | 2,500 | $232K | 8/22/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,187 | $0 | 6/30/2025 | View on chart |
| ANIK | ▲ Buy | Grant | 14,164 | $0 | 6/20/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 1,055 | $0 | 3/31/2025 | View on chart |
| AVNT | ▲ Buy | Grant | 955 | $0 | 12/31/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 775 | $0 | 9/30/2024 | View on chart |
| ANIK | ▲ Buy | Grant | 5,771 | $0 | 7/9/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 806 | $0 | 6/28/2024 | View on chart |
| ANIK | ▲ Buy | Grant | 468 | $0 | 6/3/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 808 | $0 | 3/29/2024 | View on chart |
| AVNT | ▲ Buy | Grant | 834 | $0 | 12/29/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 984 | $0 | 9/29/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 863 | $0 | 6/30/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 857 | $0 | 3/31/2023 | View on chart |
| AVNT | ▲ Buy | Grant | 1,040 | $0 | 12/31/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 1,139 | $0 | 9/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 1,139 | $0 | 9/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 880 | $0 | 6/30/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 717 | $0 | 3/31/2022 | View on chart |
| AVNT | ▲ Buy | Grant | 627 | $0 | 12/31/2021 | View on chart |
| AVNT | ▲ Buy | Grant | 744 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Avient Announces New CEO Mike Frank, Reaffirms Guidance
Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.
Avient Announces New CEO Mike Frank, Reaffirms Guidance. Avient disclosed that Mike Frank will assume the chief executive role, succeeding Dr. Ashish Khandpur. The company kept its FY2026 adjusted EPS outlook of $3.10‑$3.25 and its Q3 adjusted EPS guidance of $0.80. The leadership change was highlighted alongside a dividend champion note, and the stock fell about 7% after the news. The announcement arrives as the shares trade near a long‑standing support level.